human coagulation factor VIII at a glance
Medicine class
Plasma-derived blood coagulation factor replacement
Licensed role
Prevention and treatment of bleeding in haemophilia A
Administration
Given into a vein after mixing the powder with its supplied solvent
Important monitoring
Clinical response, factor VIII activity and development of factor VIII inhibitors
What is human coagulation factor VIII used for?
Haemoctin and Optivate are licensed for haemophilia A caused by congenital factor VIII deficiency.
Treatment of bleeding episodes
Prevention of bleeding
Bleeding management around surgery or dental procedures under specialist supervision
Haemoctin is not indicated for von Willebrand disease because it does not contain a pharmacologically effective amount of von Willebrand factor.
How does human coagulation factor VIII work?
Factor VIII works as a cofactor for activated factor IX, accelerating factor X activation. This leads to thrombin and fibrin production so a stable clot can form. Replacement temporarily corrects deficient factor VIII activity and reduces bleeding tendency.
How to take human coagulation factor VIII
Treatment should be supervised by a clinician experienced in haemophilia. People trained for home treatment should follow the product leaflet and their haemophilia team's instructions.
Mix the powder only with the solvent supplied for that product, using aseptic technique.
Gently swirl rather than vigorously shaking the vial.
Do not use a prepared solution that is cloudy, discoloured or contains deposits or particles.
Give it intravenously using the supplied or recommended equipment.
Follow the product-specific preparation instructions and record the product name and batch number.
Food does not affect an intravenous factor VIII injection.
human coagulation factor VIII side effects
Common or expected effects
- With Optivate: headache, sleepiness, dizziness, rash or itching
- With Optivate: injection-site redness, rash or pain
- With Optivate: muscle or joint stiffness, peripheral swelling, shivering or fever
Get urgent medical advice
- Severe hypersensitivity or anaphylaxis, including throat swelling, breathing difficulty, chest tightness, low blood pressure or collapse
- Factor VIII inhibitors, suspected when expected factor levels are not reached or bleeding is not controlled
- Central-line infection or catheter-associated thrombosis when a central venous access device is used
human coagulation factor VIII in pregnancy
Experience during pregnancy is limited, so factor VIII should be used only when clearly indicated following specialist assessment. Women with haemophilia or carrier status may have low factor VIII levels and need coordinated care from haemophilia and maternity teams because bleeding risk can increase during and after childbirth.
human coagulation factor VIII while breastfeeding
Experience during breastfeeding is limited. Use should be based on specialist assessment that treatment is clearly indicated; discuss feeding and treatment plans with the haemophilia and maternity teams.
human coagulation factor VIII interactions
No interactions with other medicines have been reported in the selected product information. The prepared product should not be mixed with other medicines, and only recommended administration equipment should be used.
Common questions about human coagulation factor VIII
Answers are fully visible for fast scanning and source review.
What is human coagulation factor VIII used for?
It replaces deficient factor VIII to prevent or treat bleeding in congenital haemophilia A, including specialist management around procedures.
Is it made from human plasma?
Haemoctin and Optivate are produced from donated human plasma. Donor screening and manufacturing steps reduce infection risk, but transmission of an infectious agent cannot be completely excluded.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.